Last checked at 22 Feb 2016 09:52
Hikma Appoints John Castellani to Board of Directors
London, 22 February 2016 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ("Hikma"), the FTSE 100 pharmaceuticals company, today announces the appointment of Mr. John J. Castellani as an independent non-executive director of the Company with effect from 1 March 2016. Mr. Castellani will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees.
Said Darwazah, Chairman and Chief Executive of Hikma, said: "I am delighted that John will join our Board. He brings a wealth of pharmaceutical regulatory and policy experience, particularly in the United States, as well as broad business experience. His background and expertise will further enhance our strong Board."
John J. Castellani
Mr. Castellani was President and Chief Executive Officer of Pharmaceutical Research and Manufacturers of America (PhRMA) from 2010 to 2015. Prior to that, he was the President and Chief Executive of Business Roundtable, an association of leading US company Chief Executives. During his career Mr. Castellani has also held senior positions with Burson-Marsteller, Tenneco, Inc. and General Electric Corp., amongst others.
Mr. Castellani is also a member of the board of trustees of The Johns Hopkins Medical System Sibley Memorial Hospital in Washington, DC, and a member of the board of directors of the National Patient Safety Foundation.
Mr. Castellani holds a Batchelor of Science Degree (Biology) from Union College Schenectady, New York.
There is no other information required to be disclosed in respect of Mr. Castellani's appointment under LR 9.6.13R of the Listing Rules.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC Peter Speirs, Company Secretary
Susan Ringdal, Vice President, Corporate Strategy & Investor Relations
|
+44 (0)20 7399 2772
+44 (0)20 7399 2760 |
FTI Consulting Ben Atwell / Matthew Cole |
+44 (0)20 3727 1000 |
Notes to Editors:
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. Hikma is a constituent of the FTSE 100 index of companies.